MedTrace Logo

Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan

NCT04601441 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-12-08

No results posted yet for this study

Summary

To evaluate changes in genomic alterations for 73 PC driver genes during apalutamide treatment

Conditions

  • Metastatic Castration-sensitive Prostate Cancer

Interventions

DRUG

Apalutamide

Apalutamide 240 mg administered orally once a day as four 60 mg tablets

Sponsors & Collaborators

  • Janssen Pharmaceutical K.K.

    collaborator INDUSTRY

  • Kindai University

    lead OTHER

Principal Investigators

  • Hirotsugu Uemura, MD, PhD · Department of Urology, Kindai University Faculty of Medicine

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-06
Primary Completion
2025-03-31
Completion
2025-03-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04601441 on ClinicalTrials.gov